In the EMMY trial, the initiation of SGLT2Is shortly after an acute myocardial infarction significantly reduced the N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) and had positive effects on structural and functional echocardiographic parameters after 26 weeks of treatment without notable safety concerns compared to the placebo [28]. The gene discussed is NPPB; the disease is acute myocardial infarction.